Actinobac is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Actinobac’s drug candidates are based upon Leukothera® (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera® are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis. For the millions of patients who suffer from blood cancers, autoimmune diseases, and inflammatory conditions, Actinobac offers new hope because their products specifically target and eliminate the diseased cells. This means greater benefit with fewer side effects. Actinobac’s goal is to not just change lives, but also save them.